Latest news with #NucleusNetwork
Yahoo
05-08-2025
- Business
- Yahoo
Nucleus Network收購Hammersmith Medicines Research
打造第一個真正全球化的早期臨床試驗網路 澳洲布里斯本和倫敦, August 04, 2025--(BUSINESS WIRE)--(美國商業資訊)--早期臨床研究領域的全球領導者Nucleus Network今日宣布收購英國最受推崇的早期臨床試驗機構之一Hammersmith Medicines Research (HMR)。這一里程碑事件代表Nucleus Network的全球成長進程邁出重要一步，使其成為唯一一家在澳洲、美國和英國均設有專屬設施的早期臨床研究服務提供者。 廣告 廣告 此次收購使兩家秉持共同使命——推動醫藥進步，改善人類生活——的機構實現強強聯手。這也彰顯了Malcolm Boyce博士的遺產——在他的領導下，HMR成為英國及歐洲地區早期臨床研究領域的卓越中心。憑藉互補的科學專長以及對受試者安全和倫理行為的堅定共同承諾，合併後的機構將具備獨特的優勢，能夠在三大洲加快臨床開發進程，展開包容性強、高品質的研究。 Nucleus Network執行長Teena Pisarev表示：「能夠獲得Boyce博士的信任，繼承並延續HMR的卓越傳統，這讓我們深感榮幸。此次收購的意義遠不止於擴大我們的全球業務版圖。它反映了雙方在價值觀、企業文化和使命目標上的真正契合。我們正攜手打造一個平台，將有助於重新定義早期臨床試驗的展開方式。」 樹立早期臨床試驗的新基準 透過收購HMR，Nucleus Network為早期臨床試驗的展開設立了新的全球標竿。試驗委託者如今將受惠於一種全面整合的模式，該模式兼具全球涵蓋與深厚的本地專長。借助我們全球首屈一指的跨司法管轄區業務開發團隊的實力，我們將與試驗委託者密切合作，根據其策略重點，為試驗選擇最匹配的地理位置。歸功於統一的流程和始終如一的高品質標準，研究可在一個監管環境中啟動，並順暢轉換到另一個監管環境，從而加快進度，降低營運風險。 廣告 廣告 地理版圖的擴大表示能夠接觸到更廣泛、更多元的自願者和病患群體。這種規模優勢有助於加快招募速度，實現更具包容性的研究設計——這兩點對於首次人體試驗和適應性試驗方案而言都至關重要。HMR數十年的科學與營運卓越經驗令Nucleus Network先進的基礎設施和數位化能力如虎添翼。雙方將攜手為研究執行和資料品質帶來更高的精準度，推動所有研究網站均取得可靠成果。 試驗委託者將透過統一的系統、共用的最佳實務和協調的專案交付，獲得更精簡的合作體驗，從而簡化早期臨床試驗執行過程中的複雜性。這種整合進一步鞏固了Nucleus Network身為專注於早期臨床研究領域的最具經驗全球服務提供者的地位。 廣告 廣告 與此同時，Nucleus Network將繼續與全球各地的委託研究機構(CRO)合作，提供靈活的服務，以補充現有合作夥伴關係，並擴大地理涵蓋範圍。 Pisarev補充說道：「此次收購擴大了我們為試驗委託者創造的可能性。它深化了我們的科學能力，擴大了我們的營運涵蓋範圍，並強化了我們為全球病患提供改變生命的療法的承諾。」 Nucleus Network將繼續營運其位於澳洲布里斯本、墨爾本和雪梨（約2026年起）、美國明尼蘇達州明尼亞波里斯以及英國倫敦的臨床研究中心，確保持續推進現有研究並維護可信賴的合作關係。 關於Nucleus Network Nucleus Network是唯一一家擁有全球業務版圖的早期臨床研究服務提供者，在澳洲、美國和英國均設有專屬的第一期臨床研究設施。憑藉超過20年的經驗和1500多項首次人體研究，Nucleus Network以其科學卓越性、營運誠信度和對創新的承諾而廣受肯定。 廣告 廣告 如欲瞭解更多資訊，請造訪： 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。 請前往 瀏覽源版本: Contacts 媒體連絡人 Dani Stoltzfus Mighty Spark Communications 電子郵件：dstoltzfus@ Katrina Campbell 行銷與傳播執行副總裁 Nucleus Network 電子郵件：
National Post
04-08-2025
- Business
- National Post
Nucleus Network Acquires Hammersmith Medicines Research
Article content BRISBANE, Australia & LONDON — Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom's most respected early phase clinical trial organisations. This milestone marks a significant step in Nucleus Network's global growth, establishing the only early phase provider with dedicated facilities in Australia, the United States, and the United Kingdom. Article content The acquisition brings together two organisations with a shared mission: advancing medicine and improving lives. It also honours the legacy of Dr Malcolm Boyce, whose leadership established HMR as a centre of excellence in early phase research across the UK and Europe. With complementary scientific expertise and a strong, mutual commitment to participant safety and ethical conduct, the combined organisation is well positioned to accelerate clinical development and deliver inclusive, high-quality studies across three continents. Article content 'We are deeply honoured by the trust Dr Boyce has placed in us to carry forward HMR's legacy,' said Article content . 'This acquisition is about more than expanding our global footprint. It reflects a genuine alignment of values, culture, and purpose. Together, we are building a platform that will help redefine the way early phase trials are delivered.' Article content A New Standard for Early-Phase Clinical Trials Article content With the acquisition of HMR, Nucleus Network is setting a new global benchmark in the delivery of early-phase clinical trials. Sponsors now benefit from a fully integrated model that combines global reach with deep local expertise. By harnessing the strength of our globally leading and multi-jurisdictional business development team, we will work in close partnership with sponsors to guide trials to the geographic locations that best align with their strategic priorities. Studies can commence in one regulatory environment and seamlessly transition to another, enabled by harmonised processes and consistently high-quality standards, accelerating timelines and reducing operational risk. Article content The expanded geographic footprint expands access to broader and more diverse volunteer and patient populations. This scale supports faster recruitment and more inclusive study designs, both of which are critical for first-in-human and adaptive trial protocols. HMR's decades of scientific and operational excellence complement Nucleus Network's advanced infrastructure and digital capabilities. Together, they bring added precision to study execution and data quality, driving robust outcomes across all sites. Article content Sponsors will experience more streamlined engagement through unified systems, shared best practices, and coordinated project delivery, simplifying the complexities of early-phase trial execution. This integration further strengthens Nucleus Network's position as the most experienced global provider dedicated to early-phase clinical research. Article content At the same time, Nucleus Network will continue to partner with CROs around the world, offering flexible services that complement existing partnerships and extend reach across geographies. Article content ' This acquisition expands what's possible for our sponsors,' Pisarev added. 'It deepens our scientific capabilities, strengthens our operational reach, and reinforces our commitment to delivering life-changing therapies to patients around the world.' Nucleus Network will continue to operate its clinical sites in Brisbane, Melbourne, and Sydney (from ~2026), Australia; Minneapolis, Minnesota; and London, England, ensuring continuity for ongoing studies and trusted relationships. Article content Nucleus Network is the only early-phase clinical research provider with a global footprint, operating dedicated Phase I facilities in Australia, the United States, and the United Kingdom. With over 20 years of experience and more than 1,500 first-in-human studies conducted, Nucleus Network is recognized for its scientific excellence, operational integrity, and commitment to innovation. Article content Article content Article content Article content Contacts Article content Media Contact Article content
Associated Press
04-08-2025
- Business
- Associated Press
Nucleus Network Acquires Hammersmith Medicines Research
BRISBANE, Australia & LONDON--(BUSINESS WIRE)--Aug 4, 2025-- Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom's most respected early phase clinical trial organisations. This milestone marks a significant step in Nucleus Network's global growth, establishing the only early phase provider with dedicated facilities in Australia, the United States, and the United Kingdom. This press release features multimedia. View the full release here: The acquisition brings together two organisations with a shared mission: advancing medicine and improving lives. It also honours the legacy of Dr Malcolm Boyce, whose leadership established HMR as a centre of excellence in early phase research across the UK and Europe. With complementary scientific expertise and a strong, mutual commitment to participant safety and ethical conduct, the combined organisation is well positioned to accelerate clinical development and deliver inclusive, high-quality studies across three continents. 'We are deeply honoured by the trust Dr Boyce has placed in us to carry forward HMR's legacy,' said Teena Pisarev, Chief Executive Officer of Nucleus Network . 'This acquisition is about more than expanding our global footprint. It reflects a genuine alignment of values, culture, and purpose. Together, we are building a platform that will help redefine the way early phase trials are delivered.' A New Standard for Early-Phase Clinical Trials With the acquisition of HMR, Nucleus Network is setting a new global benchmark in the delivery of early-phase clinical trials. Sponsors now benefit from a fully integrated model that combines global reach with deep local expertise. By harnessing the strength of our globally leading and multi-jurisdictional business development team, we will work in close partnership with sponsors to guide trials to the geographic locations that best align with their strategic priorities. Studies can commence in one regulatory environment and seamlessly transition to another, enabled by harmonised processes and consistently high-quality standards, accelerating timelines and reducing operational risk. The expanded geographic footprint expands access to broader and more diverse volunteer and patient populations. This scale supports faster recruitment and more inclusive study designs, both of which are critical for first-in-human and adaptive trial protocols. HMR's decades of scientific and operational excellence complement Nucleus Network's advanced infrastructure and digital capabilities. Together, they bring added precision to study execution and data quality, driving robust outcomes across all sites. Sponsors will experience more streamlined engagement through unified systems, shared best practices, and coordinated project delivery, simplifying the complexities of early-phase trial execution. This integration further strengthens Nucleus Network's position as the most experienced global provider dedicated to early-phase clinical research. At the same time, Nucleus Network will continue to partner with CROs around the world, offering flexible services that complement existing partnerships and extend reach across geographies. ' This acquisition expands what's possible for our sponsors,' Pisarev added. 'It deepens our scientific capabilities, strengthens our operational reach, and reinforces our commitment to delivering life-changing therapies to patients around the world.' Nucleus Network will continue to operate its clinical sites in Brisbane, Melbourne, and Sydney (from ~2026), Australia; Minneapolis, Minnesota; and London, England, ensuring continuity for ongoing studies and trusted relationships. About Nucleus Network Nucleus Network is the only early-phase clinical research provider with a global footprint, operating dedicated Phase I facilities in Australia, the United States, and the United Kingdom. With over 20 years of experience and more than 1,500 first-in-human studies conducted, Nucleus Network is recognized for its scientific excellence, operational integrity, and commitment to innovation. For more information, visit: View source version on CONTACT: Media ContactDani Stoltzfus Mighty Spark Communications Email:[email protected] Campbell EVP Marketing & Communications Nucleus Network Email:[email protected] KEYWORD: UNITED STATES UNITED KINGDOM AUSTRALIA/OCEANIA AUSTRALIA NEW ZEALAND IRELAND NORTH AMERICA CANADA EUROPE MINNESOTA INDUSTRY KEYWORD: BIOTECHNOLOGY OTHER HEALTH HEALTH GENERAL HEALTH PHARMACEUTICAL HEALTH TECHNOLOGY OTHER SCIENCE MEDICAL DEVICES RESEARCH SCIENCE CLINICAL TRIALS SOURCE: Nucleus Network Copyright Business Wire 2025. PUB: 08/04/2025 04:00 AM/DISC: 08/04/2025 04:00 AM
